Clinical TrialMay 31, 2026, 08:01 AM
Immunocore brenetafusp Phase 1 data: 87% 6-mo OS in advanced melanoma
AI Summary
Immunocore presented updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma at the 2026 ASCO Annual Meeting. Brenetafusp monotherapy resulted in an 87% 6-month overall survival rate and a 52% disease control rate in HLA-A*02:01-positive patients. These promising results support the selection of the 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma. The drug was generally well tolerated, with consistent clinical benefit observed even in difficult-to-treat subgroups.
Key Highlights
- Brenetafusp monotherapy achieved an 87% 6-month overall survival rate in heavily pretreated advanced melanoma patients.
- The disease control rate for brenetafusp monotherapy was 52%, with an overall response rate of 12%.
- Median overall survival for monotherapy patients was 14.3 months (95% CI: 11.3-20.4).
- The 160 mcg dose was selected for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma.
- Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance.
- Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab.
Price Impact
More from IMCR